Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met AntibodyGiovanni Pacchiana, Elisa Vigna|Journal of Biological Chemistry|2010Cited by 77
Dual Constant Domain‐Fab: A novel strategy to improve half‐life and potency of a Met therapeutic antibodySimona Cignetto, Elisa Vigna|Molecular Oncology|2016Cited by 14
A receptor-antibody hybrid hampering MET-driven metastatic spreadChiara Modica, Elisa Vigna|Journal of Experimental & Clinical Cancer Research|2021Cited by 11
Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic AntibodyChiara Modica, Elisa Vigna|Cancers|2020Cited by 3
Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor DisseminationChiara Modica, Elisa Vigna|Cancers|2023Cited by 1